October 2020

Yourgene Health signs partnership deal with blue chip Japanese company

Yourgene Health, a molecular diagnostics group which is based at Citylabs on Oxford Road, has signed a 5 year strategic partnership with a blue chip multinational Japanese company.

“We are delighted to have secured this key strategic partnership expanding and consolidating our geographical reach into Japan.This is a great endorsement of our analytical capabilities, and we are pleased to be able to customise these class-leading technology tools: Flex Software and Atlas Workflow Manager for our partner.We hope to develop future collaborations with this blue chip partner further across reproductive health and other fields.”

Yourgene Chief Executive, Lyn Rees

Oxford Road Corridor is home to Yourgene Health; an international molecular diagnostics group which develops, manages and commercialises genetic products and services, with an aim to impact human health in a positive way. The group, who collaborate with leaders in DNA technology, have now announced a partnership with a blue chip multinational Japanese company, whose name will be disclosed when the results of the collaboration are ready for commercial launch. 

In this new partnership, Yourgene Health will supply their Flex Analysis Software bioinformatics platform for a reproductive health project. This technology transfer agreement will provide the Japanese company access to their Flex Software, which was launched in 2019, and is a medical grade, configurable bioinformatics software platform that allows complex sequencing data to be examined in a user friendly way for clinicians. This will aid in the company’s pursuit of developing in vitro diagnostic product development partnerships and research collaborations with key members of the industry. 

This innovative software, when coupled with the associated knowhow that the Japanese company will receive from Yourgene Health, will enable Yourgene Health’s new partner to offer clinical screening services and bioinformatic analysis. This exciting partnership is expected to deliver over USD2.5m of revenue, and is set to create a new high standard for clinical offerings in the healthcare market. More information will be available when the results of the partnership are prepared for the market.